CN   |   EN
Drug <span>Screening</span>

Fragment-based

Drug Discovery

Home > Service > Fragment-based Drug Discovery >
Fragment-based drug screening involves the identification of small molecule fragments that weakly interact with the target protein using various interaction methods. Subsequently, based on their structural information, these active fragments are optimized to obtain lead compounds with higher activity for the development of new drugs.
ReadCrystal has established FBDD drug screening platform utilizing its biophysical platform and X-ray protein crystallography technology.

2700+ “rule of three” compliant fragments

Diverse screening methods, including SPR, TRIC, AS-MS, NanoDSF, MST, ITC

Fragments with measurable KD and co-crystal results of target proteins with small molecule fragments are available

Provide protein-small molecule fragment co-crystal structures via X-ray crystallography techniques and soaking method

Workflow
How our Fragment-based Drug Discovery service works?
  • Protein
    Production

    E. coli

    Insect cells

    Mammalian cells

    Membrane proteins

  • Assay Setup & Fragment
    Primary Screen

    SPR

    TRIC

    AS-MS

    NanoDSF

  • Hits Validation
    (Kd Confirmation & combination
    and function confirmation)

    SPR

    TRIC

    NanoDSF

    MST

    ITC

    Enzyme activity assay

  • Structure
    Determination

    Co-crystallization

    Soaking

    X-ray crystallography

    Cryo-EM SPA

Case Studies
Menin protein
View more